Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17088827 | 1.00 | CA1 (0.58) | CA1CA2HRH3ACHEEPHX1 | |
| SCHEMBL2583782 | 1.00 | CA1 (0.58) | CA1CA2HRH3ACHEEPHX1 | |
| SCHEMBL18828734 | 1.00 | CA1 (0.58) | CA1CA2HRH3ACHEEPHX1 | |
| SCHEMBL8370841 | 1.00 | CA1 (0.58) | CA1CA2HRH3ACHEEPHX1 | |
| SCHEMBL14779905 | 1.00 | CA1 (0.58) | CA1CA2HRH3ACHEEPHX1 | |
| SCHEMBL8366305 | 1.00 | CA1 (0.58) | CA1CA2HRH3ACHEEPHX1 | |
| SCHEMBL28839918 | 0.97 | CA1 (0.56) | CA1CA2HRH3ACHEEPHX1 | |
| SCHEMBL276820 | 0.97 | CA1 (0.54) | CA1CA2HRH3ACHEEPHX1 | |
| SCHEMBL10727963 | 0.93 | CA1 (0.52) | CA1CA2HRH3ACHEEPHX1 | |
| Trimethylammonium SCHEMBL21268541 | 0.93 | CA1 (0.52) | CA1CA2HRH3ACHEEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428740-A | Indazolyl-and indolyl-benzamide derivatives | 埃萨内克斯股份有限公司 | 2017-12-01 | — | — | CN | claimed |
| CN-105085264-A | Asymmetric synthesis method for tanshinol ester derivative | UNIV SHANGHAI JIAOTONG | 2015-11-25 | — | — | CN | claimed |
| EP-2035007-A1 | USE OF ADENOSINE A1 ANTAGONIST IN RADIOCONTRAST MEDIA INDUCED NEPHROPATHY | Solvay Pharmaceuticals GmbH (DE) | 2009-03-18 | — | — | EP | claimed |
| WO-2007147809-A1 | USE OF ADENOSINE A1 ANTAGONIST IN RADIOCONTRAST MEDIA INDUCED NEPHROPATHY | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-12-27 | — | — | WO | claimed |
| CN-1306336-C | Photoresist composite and pattern forming process with it | SAMSUNG ELECTRONICS CO LTD (KR) | 2007-03-21 | — | — | CN | claimed |
| CN-1432871-A | Photoresist composite and pattern forming process with it | SAMSUNG ELECTRONICS CO LTD (KR) | 2003-07-30 | — | — | CN | claimed |
| US-4454274-A | Aminoplast curable coating compositions containing cycloaliphatic sulfonic acid esters as latent acid catalysts | PPG INDUSTRIES, INC. (US) | 1984-06-12 | — | — | US | claimed |
| JP-11222448-A | — | — | None | — | — | JP | disclosed |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119715845-A | Method for detecting chlorinated impurities in lurasidone hydrochloride raw material | 山东创新药物研发有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2025049254-A1 | PYRAZOLOPYRIDINE BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4486454-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-01-08 | — | — | EP | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-4575512-A | THROMBOXANE SYNTHETASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1986-03-11 | — | — | US | disclosed |
| EP-0163562-A1 | 7-Oxabicycloheptane substituted ethers | E.R. Squibb & Sons, Inc. (US) | 1985-12-04 | — | — | EP | disclosed |
| EP-0161904-A2 | Tetrahydrofuranyl and tetrahydrothienyl substituted ethers | E.R. Squibb & Sons, Inc. (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4550120-A | BRONCHODILATOR AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1985-10-29 | — | — | US | disclosed |
| US-4542151-A | CARDIOVASCULAR, BRONCHODILATION, ANALGESICS, ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1985-09-17 | — | — | US | disclosed |
| US-4521539-A | ANALGESICS, CARDIONVASCULAR AND ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-06-04 | — | — | US | disclosed |
| US-4454274-A | Aminoplast curable coating compositions containing cycloaliphatic sulfonic acid esters as latent acid catalysts | PPG INDUSTRIES, INC. (US) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, TRPM2, PKD2 | CA1 2481/4885CA2 146/4885HRH3 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.